Floatz logo

her2bi-armed activated t cells

PSA Progression

Barbara Ann Karmanos Cancer InstituteCell therapyPhase 2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
31/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the PSA Progression cohort.

Asset / SponsorPhaseRating
Enzalutamide
Roswell Park Cancer Institute
Phase 2BB
Cyclophosphamide
Barbara Ann Karmanos Cancer Institute
Phase 2B
Pembrolizumab
Barbara Ann Karmanos Cancer Institute
Phase 2B
Carboplatin
University of Washington
Phase 2B
Epirubicin
Barbara Ann Karmanos Cancer Institute
Phase 2B

View all 20 →

Same molecule, other indications

her2bi-armed activated t cells is also rated in:

castration-resistant prostate carcinomaDormant
CC
Indicative ·
46 / 100
View asset →
metastatic prostate carcinomaDormant
CC
Indicative ·
46 / 100
View asset →
prostate adenocarcinomaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →